



## **2024 Research Grants**

---

### **GUIDELINES**

**Applications must be received by April 26, 2024, 11:59 pm PDT**

Please send applications by e-mail to:

**[info@lymphoma.ca](mailto:info@lymphoma.ca)**



## Table of Contents

Table of Contents .....	1
About Lymphoma Canada .....	2
Description of Grant .....	2
Grant Amount and Duration .....	2
Eligibility Requirements .....	2
Key Dates.....	3
Responsibilities of the Applicant .....	3
Reporting .....	4
Acknowledgement of Lymphoma Canada.....	4
Deferral of Start Date .....	4
Grant Application and Evaluation.....	4
1. Grant Application Form.....	5
• Application Information.....	5
• Project Information .....	6
2. Applicant CV .....	7
Contact Information .....	8



## About Lymphoma Canada

Lymphoma Canada (“LC”) is the only Canadian national charity focused solely on lymphoma. We raise funds to fulfil our mission – to empower patients and the lymphoma community through education, support, advocacy and research. Background information, membership of the Board of Directors and the Scientific Advisory Board and a description of activities can be found at [www.lymphoma.ca](http://www.lymphoma.ca).

## Description of Grant

The Lymphoma Canada Research Grants are intended to support small, well-defined research studies that have the potential to effect improvements in healthcare, health systems, and/or health outcomes as they pertain to malignant lymphoproliferative diseases.

Proposed research studies may address any of the following broad areas of research, including but not limited to:

- patient-reported outcomes;
- comparative clinical effectiveness;
- pharmaco-economics; or
- health care utilization.

## Grant Amount and Duration

Grants will be offered once per year.

Lymphoma Canada will provide grants up to a maximum of \$50,000, dependent on the nature and budget of the research study. Research studies are to be completed within the agreed upon term of the study but will not exceed 2 years of the grant start date.

The grant is valued in Canadian dollars and is taxable.

## Eligibility Requirements

- Applicants can be healthcare professionals or researchers at any stage of their career;
- must be eligible to work in Canada; and
- for the duration of the grant, be employed by a Canadian university, academic research institute, provincial cancer agency, or hospital.

## Key Dates

Phase	Date
Call for proposals	March 7, 2024
Application deadline	April 26, 2024, 11:59 PM (PST)
Review panel meeting	May 2024
Notification of awards	July 2024
Award start date	October 2024

## Responsibilities of the Applicant

The Principal Investigator (Applicant) and the Co-Principal Investigators (if collaborating with another investigator) must be based in, or formally affiliated with, a Canadian non-profit Sponsoring Institution at the time funding commences and for the duration of the award.

The Application will require one Principal Investigator (PI) who is responsible for the preparation and submission of the proposal including the budget, the conduct of the research programs and adherence with all stipulations made by LC, and the Grant Agreement, if funded. The Principal Investigator must be able to demonstrate a significant track record in the area of hematology and/or lymphoma research.

The applicant agrees to:

- Supervise the research and to provide the resources that are necessary for the successful completion of the research project, as appropriate.
- Use the Lymphoma Canada grant funds only for the purposes intended.
- Respect the obligations described in the Lymphoma Canada Research Grant Agreement, as well as those of the Host Institution's policies and procedures.
- Inform Lymphoma Canada and the host institution immediately of any substantive changes such as eligibility status, change of host institution or research location, etc.
- Clearly outline ALL principal investigator(s) and/or co-investigator(s) on the research application who are overseeing the research project
- Meet all reporting requirements of Lymphoma Canada in a timely fashion.

Please note the reporting deadlines (subject to change) for the 2024-2025 grant (please note these timelines assume a 1 year study, if the study extends to the



maximum term of two years then the mid term reporting will be due September 30, 2025 and the final report will be due September 30, 2026):

Phase	Timing	Date
Interim Progress Report	6-month report	March 31, 2025 (within 30 days)
Final Report	12-month report	September 30, 2025 (within 30 days)

- Comply with the ethical and research policies outlined by the host institution and the Tri-Agency Framework: Responsible Conduct of Research.

## Reporting

Progress reports are required and will be described in the award contract but should not be less than one at the end of the first term (6 months) and another upon completion of the research study. The reports must include a detailed summary of the study's progress (including scientific and lay audience summaries) and a financial statement detailing how funds were used. Annual reports are due within thirty days of the requested dates.

## Acknowledgement of Lymphoma Canada

Recipients must acknowledge the support given by Lymphoma Canada in any publication or public messages made while holding a Lymphoma Canada Research Grant or work resulting from the Grant.

## Deferral of Start Date

The Grant is offered with a **start date of October 1, 2024**. The start date cannot be deferred without previous consent of Lymphoma Canada.

## Grant Application and Evaluation

The Full Application is due: **April 26, 2024, 11:59 PM Pacific Time**

All components of the application must be completed and sent as a **single PDF document** and received by Lymphoma Canada by the deadline indicated. Incomplete or late applications will not be considered.

**Applications should be mailed electronically to: [info@lymphoma.ca](mailto:info@lymphoma.ca)**

**Please include in the subject line: Lymphoma 2024 Research Grant Applicant**



Full applications will be reviewed after the submission deadline by a peer review committee. An application that does not meet the program goals, scope or guidelines will be administratively disqualified. Applications will be assigned an initial score by the primary and secondary reviewers. Only applications that fall above a scoring level determined by program staff and the committee chair will be discussed in detail for final ranking by the entire committee. Once ranked by the peer review committee, the highest scoring proposals will be reviewed and final approval of funding will be made by Lymphoma Canada's Board of Directors. Any applicant selected for funding will be notified of the funding decision in July 2024.

Applications will be evaluated by a peer-review process that will assess:

- Feasibility of the proposed work
- Potential impact on malignant lymphoproliferative diseases
- Proposed budget

The review committee will consider the following:

- Does the project rationale logically support the proposed study, and is it feasible?
- Is the proposal well-developed, with a clear aim, design, and analysis?
- Is it reasonable to expect meaningful results to support or reject the original hypothesis within 8-12 (or up to 24) months?
- Is the budget reasonable and does not include ineligible funding?

The application consists of the following components (details provided below):

1. Grant Application Form
2. Applicant CV
3. Letter of Support

Preference for all three items (application form, CV and letter of support) to be received in one pdf package. Please keep in mind the strict page limits for each section where applicable.

## 1. Grant Application Form

- **Applicant Information**

The applicant must complete all fields in the space provided on the application form.

- a. **Contact information**

Please include information of Co-Principal Investigator (Co-PI) if applicable.

- b. **Academic or hospital affiliation**



- c. Other research funds:** List other research funds and salary support currently held and applied for your research project. Include the name of the grant(s), the term of the grant(s), and the annual amount of the grant(s). There is no limit to the amount of peer-reviewed grant support that can be held in conjunction with the LC Research Grant, provided that any additional peer-reviewed funds do not overlap with the LC Research Grant funding.

• **Project Information**

The applicant must complete all fields in the space provided on the application form.

The proposal should include the following information:

**a. Background information** (maximum 1 page)

Describe the history and nature of the research problem with reference to the existing literature. The background information should provide appropriate context of the problem in relation to theory, research, and/or practice, its scope, and the extent to which previous studies have successfully investigated the problem, noting where gaps exist that your study attempts to address.

**b. Description of proposed research** (maximum 1 page)

Please include the following in your proposal:

- Research question(s)/objective(s)
- Specific hypothesis
- Research approach and methodologies
- Project timeline
- Significance to lymphoproliferative malignancy: the applicant should clearly state how the proposed work addresses the problem of lymphoproliferative malignancies.
- Potential for creation of new knowledge
- How the research proposed addresses a significant need or gap in the understanding, diagnosis, and/or treatment of lymphoma in Canada.

**c. Detailed project budget** (maximum 1 page)

There should be a full listing of funds required for the entire duration of funding. The maximum total cost cannot exceed \$50,000. The following expenditures are eligible for funding:



#### Salaries

- Salaries of research assistants, technicians, project coordinators and other personnel who will enhance the collaborative research productivity of the research team;
- Stipends paid to trainees (e.g., undergraduate, graduate students, postdoctoral fellows) shall be in accordance with institutional policies.

#### Direct research operating costs for the proposed research

- Small equipment items must be relevant to the research project and justification must be provided
- Materials and supplies
- Services
- Knowledge Translation activities which can include: publication costs relating to the funded research, other knowledge dissemination activities (up to a maximum of \$3,000 of the total budget including applicable taxes).

#### The following expenditures are **NOT** eligible for funding received through this funding opportunity:

- Patent-related expenses
- Travel
- Indirect costs associated with the conduct of research (including, but are not limited to, heating, lighting, ethics review, intellectual property and commercialization activities);
- Fringe benefits for students, postdoctoral fellows and clinical research fellows
- Entertainment and hospitality costs
- Membership fees, data repository/access fees, union dues, tuition, books and journals

#### d. **Appendices** (maximum 1 page): References; figures and tables

## 2. Applicant CV

The applicant's CV may be submitted in any format and should cover their entire career. The applicant's CV should contain the following information: previous education and professional training; previous research; list of publications and presentations (public and invited); grants.

A CV must be provided for all principal and co-principal investigator(s) overseeing the indicated research project.





### 3. Letter of Support

There is no requirement as to who this letter of support can be provided by. However, the letter should:

- Describe the applicant's personal characteristics (intellectual curiosity, leadership qualities, demonstrated interests and resourcefulness, commitment to research career, etc.)
- Provide specific details about the recognized or potential research experience (scientific training, research experience, mentoring experience, collaborations, potential to carry out independent research, etc.)

### Contact Information

For questions about the Lymphoma Canada Research Grant, please contact:

**Gurjot Basra**

Manager of Patient Programs, Advocacy and Research

905.858.5967

1.866.658.5556

[gurjot@lymphoma.ca](mailto:gurjot@lymphoma.ca)